---
title: "Inflammatory Pain Models"
canonical: "https://www.pharmalegacy.com/indications/cns-disease-models/neurodegenerative-diseases/aging-studies/"
lastmod: "2026-08-06T03:23:16+00:00"
generator: "llm-mirrors/1.0.19"
---

# INFLAMMATORY PAIN
PharmaLegacy has the expertise and models you need to advance your inflammatory pain program.

✕

Let PharmaLegacy provide the answers you need.

MODELS / SERVICES

λ-Carrageenan-Induced Inflammatory Pain Model in Mouse ▼

Case Study - λ-Carrageenan-induced inflammatory pain model in mouse & Endpoint Measurements

The λ-carrageenan-induced inflammatory pain model is a well-established and widely used acute inflammation model for evaluating analgesic and anti-inflammatory therapies. Local administration of λ-carrageenan produces rapid and reproducible inflammatory responses characterized by paw edema, mechanical hypersensitivity, and activation of inflammatory mediators, closely reflecting key features of acute inflammatory pain.
PharmaLegacy has established a robust λ-carrageenan model with comprehensive assessment of both pain-related and inflammatory endpoints. Mechanical hypersensitivity is routinely evaluated using von Frey testing, while paw edema is quantified through toe volume measurements, providing sensitive and complementary indicators of inflammation severity and therapeutic efficacy.
The pharmacological validity of the model has been confirmed using dexamethasone, a clinically established anti-inflammatory agent, which significantly attenuates carrageenan-induced edema and mechanical hypersensitivity. These results demonstrate the suitability of the model for evaluating anti-inflammatory compounds, analgesics, biologics, and novel therapeutic modalities.
In addition to behavioral assessments, the model can be integrated with biomarker analysis, histopathology, and cytokine profiling to investigate inflammatory mechanisms and treatment responses. This platform is widely applicable for preclinical development of therapies targeting inflammatory pain, acute inflammation, and immune-mediated disorders.

Paw Withdrawal Threshold & Toe Volume

Complete Freud’s Adjuvant (CFA) Induced Inflammatory Pain Model in Mouse ▼

Case Study - Complete Freud’s adjuvant (CFA) induced inflammatory pain model in mouse & Endpoint Measurements

The Complete Freund’s Adjuvant (CFA)-induced pain model is a well-established and widely used model of persistent inflammatory pain. Intraplantar injection of CFA produces robust local inflammation characterized by mechanical allodynia, thermal hypersensitivity, paw swelling, and sustained activation of inflammatory pathways, closely resembling chronic inflammatory pain conditions observed in patients.
PharmaLegacy has established a reliable CFA model with comprehensive behavioral assessment capabilities, including von Frey testing for mechanical hypersensitivity and Hargreaves testing for thermal sensitivity. These complementary endpoints enable sensitive evaluation of pain development, disease progression, and therapeutic efficacy over both acute and chronic phases of inflammation.
The translational relevance of the model has been validated using clinically established analgesics, including pregabalin, as well as investigational compounds targeting inflammatory pain pathways. The model provides a robust platform for evaluating small molecules, biologics, antibodies, oligonucleotide therapeutics, and other emerging treatment modalities.
In addition to behavioral assessments, the CFA model can be integrated with histopathology, immunohistochemistry, cytokine profiling, molecular biomarker analysis, and transcriptomic approaches to investigate inflammatory mechanisms, target engagement, and treatment responses. This platform is broadly applicable for preclinical development programs focused on inflammatory pain, arthritis-related pain, immune-mediated disorders, and chronic pain therapeutics.

von Frey & Hargreaves Test

Quality that never gets old:

FDA Part 11 compliant
Adherence to international GLP and QA best practices
AAALAC accredited
Scientific staff average 15+ years of experience
Supported 600+ NDAs

Advance your inflammatory pain program with robust, translational preclinical data. Contact PharmaLegacy today.

✕

Let PharmaLegacy provide the answers you need.

We’re ready when you are.             Tell us your inflammatory pain pipeline challenges.

+86-21-6176-5100*8051
+1-617-803-9415

info@pharmalegacy.com

✕

Csv Download